My passion is working in health economics, with the ultimate goal of improving patients’ quality of life and saving lives by helping bring important products to market. I couldn’t have imagined the scale of impact we’ve achieved.
Over my nine years at FIECON, we've positively impacted 13 million lives and donated over one million to wider societal causes. That’s what motivates me to keep striving. Contributing to meaningful projects and being a thought leader in the HEOR space has been incredibly rewarding. What began as an academic interest has become a truly impactful and inspiring career.
Absolutely. When we worked in the ovarian cancer space, there hadn’t been a new product on the market for about 20 years. It was a challenging submission, but it allowed us to apply our technical expertise and practical delivery, particularly in data modeling using standard practices.
Due to immature data, which is common in oncology, we couldn’t easily demonstrate the product’s value. However, we developed validated, creative solutions that met rigorous HTA standards. Notably, we established a progression-free survival (PFS) to overall survival (OS) relationship, a novel approach at the time. Despite multiple committee meetings and questions during the NICE process, we secured a positive outcome. We also extended that success to other European markets.
It was incredibly rewarding to help bring a new treatment to ovarian cancer patients after decades of limited options.
The first step, the data deep dive and gap analysis, is absolutely critical. It allows us to take a fresh perspective on the existing evidence, to understand not only what is there and what is missing, but also to identify the key drivers and levers that will truly influence outcomes. This helps us focus time, resources, and efforts on what will have the greatest impact, whether that is on cost-effectiveness results or the outcome of an HTA submission.
The "eureka" moment often comes from identifying the critical success factors early on what needs to be as robust as possible so we can clearly demonstrate the product’s value. Gaining this understanding from the outset is essential. It helps shape a focused strategy that we align with the client as we move forward.
We also consider key areas such as clinical value and cost-effectiveness, along with the perspectives of all stakeholders.
While HTA submissions follow a structured process, we remain mindful of the key opportunities to influence decisions. This involves engaging the right stakeholders, from patients to clinicians, to ensure the strategy is well-defined from the start and continues to evolve with input throughout the process.
Since I was the first employee, our team has grown to over 100 members. Now as part of FIECON under Herspiegel, a US-based leader in commercialisation services, and following the acquisition of Decisive Consulting, we are now a new global powerhouse in Access, HEOR, and go-to-market strategy.
This expansion merges Decisive’s global market access and “Rebel Thinking” with Herspiegel’s top commercialisation services, creating a strong team delivering strategy and execution across the product lifecycle. Combining FIECON’s HEOR and HTA expertise with Herspiegel’s US market access capabilities, the services help clients tackle challenges and seize opportunities from early strategy to launch and market optimisation.
Holly was employee Number 1 when she joined FIECON in 2016!
Holly has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has been instrumental in more than 30 successful HTA submissions, including to NICE, SMC and AWMSG in the UK, and several countries across Europe. Having attended and represented pharmaceutical companies at NICE and AWMSG appraisal committee meetings. She also led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Holly has conducted over 75 HEOR projects helping our clients navigate complex healthcare landscapes, including systematic literature reviews, early and HTA-ready cost-effectiveness and budget impact models, feasibility assessments and indirect comparisons, and statistical analyses including survival and HRQoL analyses. Along with having managed a range of value communication materials including user guides, technical reports, conference proceedings and publications.
